Literature DB >> 2053756

[Transzygomatic approach of the infratemporal fossa. Value and limits].

P Bordure1, F Legent, R Robert, A de Kersaint Gilly, C Beauvillain, M L Launay.   

Abstract

We report about one case of neurofibroma in the infratemporal fossa, which was treated surgically through a transzygomatic approach. Lowering the zygomatic arch with the masseter muscle and raising the coronoid process with the temporalis muscles provides a wide access to the infratemporal region without any mutilation. This way of approach can be widened anteriorly towards the orbital frame in order to reach lateral orbital lesions, and posteriorly towards the mastoideum to resect large tumors extending into the base of the skull. The transzygomatic approach seems to be particularly appropriate for the exeresis of benign tumors in the infratemporal region.

Entities:  

Mesh:

Year:  1991        PMID: 2053756

Source DB:  PubMed          Journal:  Ann Otolaryngol Chir Cervicofac        ISSN: 0003-438X


  5 in total

1.  A lateral transzygomatic-transtemporal approach to the infratemporal fossa: technical note for mobilization of the second and third branches of the trigeminal nerve.

Authors:  S Terasaka; Y Sawamura; S Goto; T Fukushima
Journal:  Skull Base Surg       Date:  1999

2.  The pterygoid venous plexuses.

Authors:  S Deplus; D Brémond-Gignac; C Gillot; J P Lassau
Journal:  Surg Radiol Anat       Date:  1996       Impact factor: 1.246

3.  The transzygomatic approach: a long-term clinical review.

Authors:  S Honeybul; G Neil-Dwyer; D A Lang; B T Evans; P D Lees
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  The orbitozygomatic infratemporal fossa approach: a quantitative anatomical study.

Authors:  S Honeybul; G Neil-Dwyer; P D Lees; B T Evans; D A Lang
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  Neurofibroma of infratemporal fossa.

Authors:  N Sonkhya; A Luckwani; P Mishra
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2001-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.